The trial is called EVOLUTION.
This trial is adding to Lutetium-177 treatment, two immunotherapy drugs - the checkpoint inhibitors ipilimumab and nivolumab.
Immune checkpoints are key regulators of the immune system
Yervoy (ipilimumab) blocks checkpoint CTLA-4
Opdivo (nivolumab) and Keytruda (pembrolizumab) block checkpoint CD-1
Now mostly used for melanoma and lung cancer.
As you can see from the Contacts on the bible of clinical trials it is being offered in many hospitals around Australia.
It is being organised by the cross-Tasman research organisation ANZUP